See more : Tokio Marine Holdings, Inc. (TKOMF) Income Statement Analysis – Financial Results
Complete financial analysis of IN8bio, Inc. (INAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IN8bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Genmab A/S (GNMSF) Income Statement Analysis – Financial Results
- Goodfellow Inc. (GDL.TO) Income Statement Analysis – Financial Results
- POET Technologies Inc. (PTK.V) Income Statement Analysis – Financial Results
- Merchants Bancorp (MBINP) Income Statement Analysis – Financial Results
- SymBio Pharmaceuticals Limited (4582.T) Income Statement Analysis – Financial Results
IN8bio, Inc. (INAB)
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.50M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| Gross Profit | -2.50M | -1.10M | -251.00K | -96.00K | -96.00K | -96.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 16.83M | 14.06M | 7.35M | 5.38M | 2.36M | 581.00K |
| General & Administrative | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.51M | 14.46M | 7.31M | 3.18M | 2.71M | 1.42M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -63.00K |
| Operating Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Cost & Expenses | 30.34M | 28.52M | 14.65M | 8.56M | 5.07M | 2.00M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00K |
| Depreciation & Amortization | 1.83M | 1.10M | 251.00K | 96.00K | 96.00K | 96.00K |
| EBITDA | -28.50M | -27.42M | -14.40M | -8.47M | -5.04M | -1.97M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -30.34M | -28.52M | -14.65M | -8.56M | -5.13M | -2.00M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 330.00K | 0.00 | 0.00 | 0.00 | 0.00 | -77.00K |
| Income Before Tax | -30.01M | -28.52M | -14.65M | -8.56M | -5.13M | -2.08M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.10M | 551.44K | -118.30K | -68.00K | -63.00K |
| Net Income | -30.01M | -27.42M | -14.65M | -8.56M | -5.13M | -2.08M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| EPS Diluted | -1.00 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| Weighted Avg Shares Out | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
| Weighted Avg Shares Out (Dil) | 29.86M | 20.97M | 18.78M | 19.35M | 19.35M | 6.17M |
IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals
NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today highlighted recent business updates and provided pipeline goals for 2024.
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia
NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced positive updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic...
IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement
Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors.
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia
NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the Company will host a conference call on Tuesday, December 12, 2023 at 8:30...
Here's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom Fisher
IN8bio, Inc. (INAB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near...
IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma
All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting
Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs) poster NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB),...
IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results, operational highlights and recent corporate developments for the third quarter ended September 30,...
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new biological correlative data from the ongoing Phase 1 clinical trial of INB-200 targeting...
Source: https://incomestatements.info
Category: Stock Reports